Zobrazeno 1 - 10
of 23
pro vyhledávání: '"L C Platanias"'
Publikováno v:
The Journal of Immunology. 158:2390-2397
During engagement of the type I IFN receptor, IRS-1 is phosphorylated on tyrosine and associates with the p85 regulatory subunit of the phosphatidylinositol (PI) 3'-kinase, which is a dual-specificity enzyme possessing both lipid and serine kinase ac
Publikováno v:
The Journal of Immunology. 150:3382-3388
We studied the association of the alpha subunit of the (IFN-alpha-receptor) to other receptor components in the human H-929 and U-266 myeloma cell lines. Immunoprecipitation performed with the IFNaR3 mAb showed that two proteins with molecular masses
Publikováno v:
Blood. 80:744-749
Homozygous and hemizygous deletions of the interferon A (IFNA) and IFNB genes have been frequently observed in acute leukemia cell lines, primary acute leukemia cases, and gliomas. Because IFNs have an antiproliferative effect, selection against the
Autor:
O R Colamonici, L M Pfeffer, F D'Alessandro, L C Platanias, S A Gregory, A Rosolen, R Nordan, R A Cruciani, M O Diaz
Publikováno v:
The Journal of Immunology. 148:2126-2132
The structure of IFN-alpha receptor was studied by 1) developing antibodies against the receptor, and 2) screening a number of cell lines by affinity cross-linking to identify cells that express different IFN-alpha 2 receptor structures. We report th
Autor:
I M, Grumbach, I A, Mayer, S, Uddin, F, Lekmine, B, Majchrzak, H, Yamauchi, S, Fujita, B, Druker, E N, Fish, L C, Platanias
Publikováno v:
British journal of haematology. 112(2)
Interferon alpha (IFNalpha) has significant clinical activity in the treatment of patients with chronic myelogenous leukaemia (CML), but the mechanisms of its selective efficacy in the treatment of the disease are unknown. The CrkL adaptor protein in
Publikováno v:
Blood. 94(1)
All-trans retinoic acid (ATRA) has previously been shown to inhibit the growth of OPM-2 human myeloma cells. The growth inhibition was postulated to result from a transcriptional downregulation of interleukin-6 receptor alpha (IL-6Ralpha) with IL-6Rb
Autor:
O W, Nadeau, P, Domanski, A, Usacheva, S, Uddin, L C, Platanias, P, Pitha, R, Raz, D, Levy, B, Majchrzak, E, Fish, O R, Colamonici
Publikováno v:
The Journal of biological chemistry. 274(7)
The precise role of the different subunits (alpha/IFNAR1 and betaL/IFNAR2) of the type I interferon receptor (IFN-R) in the activation of signal transducer and activator of transcription (Stat) 1, Stat2, and Stat3 has not yet been established. In thi
Autor:
C F, LeMaistre, M N, Saleh, T M, Kuzel, F, Foss, L C, Platanias, G, Schwartz, M, Ratain, A, Rook, C O, Freytes, F, Craig, J, Reuben, J C, Nichols
Publikováno v:
Blood. 91(2)
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics, and possible antitumor activity of a ligand fusion-protein, DAB389IL-2, in a phase I trial. This was a multicenter, open-label, dose-escalation trial. Patients with
Autor:
W H, Sun, C, Pabon, Y, Alsayed, P P, Huang, S, Jandeska, S, Uddin, L C, Platanias, S T, Rosen
Publikováno v:
Blood. 91(2)
Interferon-alpha (IFN alpha) mediates its biological effects through activation of the JAK-STAT signaling pathway and it has been shown to be one of most effective therapeutic agents for a number of hematological malignancies, including cutaneous T-c
Autor:
S, Uddin, E N, Fish, D, Sher, C, Gardziola, O R, Colamonici, M, Kellum, P M, Pitha, M F, White, L C, Platanias
Publikováno v:
Blood. 90(7)
Binding of interferon-alpha (IFN-alpha) to its receptor on hematopoietic cells activates the signal transducers and activators of transcription (Stat)- and insulin receptor substrate (IRS)-pathways, and regulates expression of antiproliferative and a